10x Genomics, Inc. (TXG) Down 6.9% — Is This My Exit Signal?
10x Genomics, Inc. (TXG) ceded ground in today's session, last trading at $75.12 — down $3.98, or 6.91%, from the prior close of $79.10. The move comes just one day after the stock hit a 52-week high of $82.68 on September 22, 2026, making today's pullback all the more abrupt. At current levels, TXG sits roughly 9.2% below that peak and remains far removed from its 52-week low of $11.16 — a reminder of how dramatic the run-up has been and how much ground has been covered in a compressed timeframe.
Volume came in at approximately 2.26 million shares, running below the 90-day average of around 3.13 million. The lighter turnover on a down day suggests this is not panic-driven liquidation, though it does little to soften the price damage. The session range of $76.61 to $81.93, reported by Yahoo Finance, confirms a wide intraday spread that reflects genuine uncertainty about where the stock finds support.
Why 10x Genomics, Inc. Price is Moving Lower
Today's decline appears rooted in profit-taking following an extreme rally, compounded by valuation concerns and institutional selling pressure. As recently as September 19, TXG had surged roughly 4.9-fold over the prior 12 months and was trading at approximately 16.2 times sales — a significant premium to the biotech industry multiple of 4.3 times and peers at 5.9 times. At those levels, even a pause in momentum can trigger a swift correction, and that appears to be precisely what transpired. The stock had simply outrun its fundamentals, leaving it exposed once buyer enthusiasm began to wane.
Institutional supply added another layer of pressure. The ARK Genomic Revolution ETF sold more than $2.5 million worth of TXG on September 22 — the same day the stock touched its 52-week high. That kind of fund-level selling introduces meaningful supply at elevated prices and can accelerate a reversal, particularly when retail and momentum investors are already sitting on outsized gains and looking for an exit. The combination of a stretched valuation, a high-profile fund trimming its position, and a stock at all-time highs created a fragile setup that today's session exposed.
The underlying fundamentals offer little counterbalance for investors seeking a reason to hold through the turbulence. The most recent earnings report, released on August 6, was fundamentally mixed at best: while adjusted EPS came in at a $0.14 loss versus the $0.24 expected loss — a $0.10 beat — and revenue of $151.04 million edged past the $146.67 million consensus, the year-over-year picture was considerably darker. Revenue fell 12.7% from $172.91 million in the prior-year period, and net income swung from a $34.5 million profit to a $17.9 million loss. Instrument revenue declined sharply as well. With the business still generating losses and top-line growth in reverse, the stock's recent rally was a momentum and sentiment story — and those stories tend to unwind quickly when the tide turns.
What is the 10x Genomics, Inc. Rating - Should I Sell?
Weiss Ratings assigns TXG a D- rating. The rating was upgraded on 12/29/2025. Current recommendation is Sell.
The sub-index profile reinforces the cautious stance. Revenue declined 12.65% year over year, the profit margin stands at -12.17%, and EPS is -$0.59 — figures that together earn a Fair Growth Index and signal a business still burning cash rather than compounding it. For a company in the capital-intensive genomics instrumentation space, where hardware cycles and consumables attach rates drive long-term economics, a shrinking top line and widening losses represent a meaningful structural concern, not merely a temporary blip. The Very Weak Efficiency Index reflects how poorly the company is converting its resources into returns — a critical watch point as R&D spending continues to weigh on margins.
The Weak Volatility Index is equally relevant given today's session. TXG's history of wide price swings means investors must be prepared for drawdowns that can be both swift and deep — the 52-week range of $11.16 to $82.68 illustrates the magnitude of price dislocations this stock is capable of producing. The Fair Total Return Index suggests that even with the recent rally factored in, risk-adjusted performance has not been particularly compelling for disciplined investors. On a more constructive note, the Excellent Solvency Index indicates the balance sheet is not an immediate distress signal — the company maintains adequate financial footing to continue operating, even as losses accumulate.
Within the Health Care sector, 10x Genomics is on par with with Moderna, Inc. (MRNA, D-), Natera, Inc. (NTRA, D-), and Revolution Medicines, Inc. (RVMD, D-), while ranking below Chugai Pharmaceutical Co., Ltd. (CHGCF, D) and Zoetis Inc. (ZTS, D). None of these comparisons offer much reassurance — across this peer group, the Sell designation is consistent, and the risk profile is uniformly elevated.
About 10x Genomics, Inc.
10x Genomics, Inc. (TXG) is a Health Care company focused on developing instruments, consumables, and software that give researchers the tools to analyze biological systems at extraordinary resolution. Headquartered in Pleasanton, California and incorporated in 2012, the company serves academic institutions, government agencies, biopharmaceutical companies, biotechnology firms, and other research organizations across the United States, the Americas, Europe, the Middle East, Africa, China, and the broader Asia Pacific region.
The company's flagship platforms span single-cell and spatial biology. Its Chromium platform enables single-cell analysis through microfluidic chips, consumables, and instruments including the Chromium X Series — along with QuantumScale kits for single-cell RNA and methylation applications. The Visium platform uses high-density DNA arrays to map the physical location of biological analytes within tissue samples, supported by the CytAssist instrument that streamlines workflow by transferring transcriptomic analytes from standard glass slides. The Xenium Analyzer rounds out the portfolio, enabling in situ detection of hundreds of RNA targets within fresh frozen or FFPE tissue sections without conventional sequencing — a capability that is difficult to replicate and central to the company's competitive positioning in spatial transcriptomics.
Supporting these hardware platforms is a suite of proprietary software tools — Cell Ranger for single-cell RNA-seq processing, Loupe Browser for data visualization, and Xenium Explorer for in situ spatial analysis. Together, these products create an integrated ecosystem that deepens customer dependency and supports recurring consumables revenue. The company's intellectual property portfolio and precision manufacturing capabilities represent genuine barriers to entry, though translating those technical advantages into consistent profitability remains the central challenge the business has yet to solve.
Investor Outlook
10x Genomics, Inc. (TXG) carries a Weiss Rating of D- (Sell), and today's sharp pullback from a 52-week high underscores the risks that come with a stock trading at 16-plus times sales while posting declining revenue and widening net losses. Investors should watch closely whether the balance sheet's current strength can sustain the company through continued operational losses, and whether instrument demand shows any signs of stabilization in upcoming quarterly results. See full rankings of all D--rated Health Care stocks inside the Weiss Stock Screener.
--